uniQure NV logo

uniQure NV - Class B

1
1
NAS:QURE (Netherlands)   Class B
$ 5.20 -0.21 (-3.88%) 11:09 PM EST
At Loss
P/B:
1.20
Market Cap:
$ 248.76M
Enterprise V:
$ -220.68M
Volume:
764.33K
Avg Vol (2M):
1.11M
Also Trade In:
Volume:
764.33K
At Loss
Avg Vol (2M):
1.11M
PE Ratio PS Ratio PB Ratio Price-to-FCF Market Cap
Current and historical daily PE Ratio for uniQure NV ( ) from 2014 to Mar 29 2024. The price to earnings ratio is calculated by taking the current stock price and dividing it by the most recent trailing twelve-month earnings per share (EPS) number. The data is updated every 20 minutes during market hours. The PE ratio can be viewed as the number of years it takes for the company to earn back the price you pay for the stock. Therefore, lower-P/E stocks are more attractive than higher P/E stocks so long as the PE ratio is positive. Also for stocks with the same PE ratio, the one with faster growth business is more attractive. uniQure NV stock (QURE) PE ratio as of Mar 29 2024 is 0. More Details

uniQure NV (QURE) PE Ratio (TTM) Chart

To

uniQure NV (QURE) PE Ratio (TTM) Historical Data

Total 1197
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 14
uniQure NV PE Ratio (TTM) Historical Data
Date PE Ratio (TTM) Data Date PE Ratio (TTM) Data
2024-03-29 At Loss 2024-01-25 At Loss
2024-03-28 At Loss 2024-01-24 At Loss
2024-03-27 At Loss 2024-01-23 At Loss
2024-03-26 At Loss 2024-01-22 At Loss
2024-03-25 At Loss 2024-01-19 At Loss
2024-03-22 At Loss 2024-01-18 At Loss
2024-03-21 At Loss 2024-01-17 At Loss
2024-03-20 At Loss 2024-01-16 At Loss
2024-03-19 At Loss 2024-01-12 At Loss
2024-03-18 At Loss 2024-01-11 At Loss
2024-03-15 At Loss 2024-01-10 At Loss
2024-03-14 At Loss 2024-01-09 At Loss
2024-03-13 At Loss 2024-01-08 At Loss
2024-03-12 At Loss 2024-01-05 At Loss
2024-03-11 At Loss 2024-01-04 At Loss
2024-03-08 At Loss 2024-01-03 At Loss
2024-03-07 At Loss 2024-01-02 At Loss
2024-03-06 At Loss 2023-12-29 At Loss
2024-03-05 At Loss 2023-12-28 At Loss
2024-03-04 At Loss 2023-12-27 At Loss
2024-03-01 At Loss 2023-12-26 At Loss
2024-02-29 At Loss 2023-12-22 At Loss
2024-02-28 At Loss 2023-12-21 At Loss
2024-02-27 At Loss 2023-12-20 At Loss
2024-02-26 At Loss 2023-12-19 At Loss
2024-02-23 At Loss 2023-12-18 At Loss
2024-02-22 At Loss 2023-12-15 At Loss
2024-02-21 At Loss 2023-12-14 At Loss
2024-02-20 At Loss 2023-12-13 At Loss
2024-02-16 At Loss 2023-12-12 At Loss
2024-02-15 At Loss 2023-12-11 At Loss
2024-02-14 At Loss 2023-12-08 At Loss
2024-02-13 At Loss 2023-12-07 At Loss
2024-02-12 At Loss 2023-12-06 At Loss
2024-02-09 At Loss 2023-12-05 At Loss
2024-02-08 At Loss 2023-12-04 At Loss
2024-02-07 At Loss 2023-12-01 At Loss
2024-02-06 At Loss 2023-11-30 At Loss
2024-02-05 At Loss 2023-11-29 At Loss
2024-02-02 At Loss 2023-11-28 At Loss
2024-02-01 At Loss 2023-11-27 At Loss
2024-01-31 At Loss 2023-11-24 At Loss
2024-01-30 At Loss 2023-11-22 At Loss
2024-01-29 At Loss 2023-11-21 At Loss
2024-01-26 At Loss 2023-11-20 At Loss

uniQure NV (QURE) PE Ratio (TTM) Comparison

Company Market Cap(Mil) PE Ratio (TTM)

Business Description

Business Description

Description
uniQure NV is a gene therapy company. It develops treatments and platforms for patients suffering from genetic and other devastating diseases. Its products and services are focused on hemophilia, Huntington's disease, and cardiovascular diseases. The company is focused on the development of the pipeline of gene therapies with the collaboration of Bristol Myers Squibb for cardiovascular diseases.